Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.

ABSTRACT:

Abstract

The determination of the genetic subtypes of primary central nervous system lymphoma (PCNSL) and their relationship to differential chemoimmunotherapeutic response has not been established. There is a particular need for genomic biomarkers that identify patients with newly diagnosed PCNSL at high risk of early progression and death. We applied targeted next-generation sequencing for detection of recurrent single-nucleotide variants, copy number alterations, and zygosity abnormalities in diagnostic specimens from 78 patients with PCNSL treated with a standard methotrexate-based regimen, to identify prognostically significant molecular subgroups. All patients received induction immunochemotherapy, and 44 proceeded to dose-intensive consolidation. Genomic aberrations at 4 loc

SUBMITTER: Geng H 

PROVIDER: S-EPMC11914178 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature